Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published January 2018 | Accepted Version + Supplemental Material
Journal Article Open

DCC mutation update: Congenital mirror movements, isolated agenesis of the corpus callosum, and developmental split brain syndrome

Abstract

The deleted in colorectal cancer (DCC) gene encodes the netrin‐1 (NTN1) receptor DCC, a transmembrane protein required for the guidance of commissural axons. Germline DCC mutations disrupt the development of predominantly commissural tracts in the central nervous system (CNS) and cause a spectrum of neurological disorders. Monoallelic, missense, and predicted loss‐of‐function DCC mutations cause congenital mirror movements, isolated agenesis of the corpus callosum (ACC), or both. Biallelic, predicted loss‐of‐function DCC mutations cause developmental split brain syndrome (DSBS). Although the underlying molecular mechanisms leading to disease remain poorly understood, they are thought to stem from reduced or perturbed NTN1 signaling. Here, we review the 26 reported DCC mutations associated with abnormal CNS development in humans, including 14 missense and 12 predicted loss‐of‐function mutations, and discuss their associated clinical characteristics and diagnostic features. We provide an update on the observed genotype–phenotype relationships of congenital mirror movements, isolated ACC and DSBS, and correlate this to our current understanding of the biological function of DCC in the development of the CNS. All mutations and their associated phenotypes were deposited into a locus‐specific LOVD (https://databases.lovd.nl/shared/genes/DCC).

Additional Information

© 2017 Wiley Periodicals, Inc. Issue Online: 07 December 2017; Version of Record online: 11 November 2017; Accepted manuscript online: 25 October 2017; Manuscript accepted: 11 October 2017; Manuscript revised: 08 October 2017; Manuscript received: 13 August 2017. The authors gratefully acknowledge the participation of the patients and their families in these studies and the support of the Australian Disorders of the Corpus Callosum (AusDoCC) organization, as well as the generous financial support of the Lefroy and Handbury families. The authors also acknowledge and thank Ivo Fokkema and Johan T. den Dunnen from the Leiden University Medical Center for their assistance in establishing the DCC LOVD. This work was funded in part by the National Health and Medical Research Council (NHMRC) Australia Project Grants (GNT1059666 to PJL and GNT1126153 to LJR, EHS and RJL), the Campbell Edwards Trust, the Victorian Government's Operational Infrastructure Support Program, the Australian Government NHMRC IRIISS and the Repository Core for Neurological Disorders, Department of Neurology, Boston Children's Hospital, and NIH IDDRC 1U54 HD090255. APLM was supported by an Australian Postgraduate Award, TJE was supported by a University of Queensland Research Scholarship, LJR was supported by an NHMRC Principal Research Fellowship and PJL was supported by a NHMRC Career Development Fellowship (GNT1032364). Disclosure statement: AM received travel funding from Zambon Company and AbbVie Inc. ER has received research support from Merz-Pharma, Orkyn, Aguettant, IP Santé, Ultragenix, IPSEN, Association Française pour l'Hémiplégie Alternante, AMADYS; served on scientific advisory boards for Orkyn, Ultragenix, Retrophin and Merz Pharma; received speech honoraria from Orkyn, Aguettant, Merz Pharma and Ultragenix; and received travel funding from the Dystonia Coalition, the Dystonia Medical Research Foundation, the Movement Disorders Society, and the European Academy of Neurology. SSJ is co-founder of Global Gene Corporation. TWY is co-founder of and part-time consultant to Claritas Genomics. This work was funded in part by the National Health and Medical Research Council (NHMRC) Australia Project Grants (GNT1059666 to PJL and GNT1126153 to LJR, EHS and RJL), the Campbell Edwards Trust, the Victorian Government's Operational Infrastructure Support Program, the Australian Government NHMRC IRIISS and the Repository Core for Neurological Disorders, Department of Neurology, Boston Children's Hospital, and NIH IDDRC 1U54 HD090255. APLM was supported by an Australian Postgraduate Award, TJE was supported by a University of Queensland Research Scholarship, ER received research support from foundation Desmarest, LJR was supported by an NHMRC Principal Research Fellowship and PJL was supported by a NHMRC Career Development Fellowship (GNT1032364).

Attached Files

Accepted Version - nihms919809.pdf

Supplemental Material - humu23361-sup-0001-suppmat.pdf

Files

humu23361-sup-0001-suppmat.pdf
Files (4.0 MB)
Name Size Download all
md5:69debaa2128daa778970c2f463134c9e
1.7 MB Preview Download
md5:acec39c66a92221aa505dc957c8b12a5
2.4 MB Preview Download

Additional details

Created:
August 21, 2023
Modified:
October 23, 2023